Johann Christoph Brandes

US Patent:

20110159504, Jun 30, 2011

Filed:

May 8, 2009

Appl. No.:

12/991647

Inventors:

James G. Herman - Lutherville MD, US
Malcolm V. Brock - Owings Mills MD, US
Johann C. Brandes - Baltimore MD, US

Assignee:

THE JOHNS HOPKINS UNIVERSITY - Baltimore MD

International Classification:

C12Q 1/68

US Classification:

435 612

Abstract:

The present invention relates to the use of nucleic acid methylation and methylation profiles to detect predict sensitivity of cells to cytotoxic chemotherapies, and in particular to microtubule based therapies, for example taxanes. The invention relates to methods for identifying a methylation profile of the checkpoint with forkhead and ring finger domains gene (CHFR) that is associated with a sensitivity to agents directed at the microtubule.

US Patent:

20160095859, Apr 7, 2016

Filed:

Oct 7, 2015

Appl. No.:

14/877203

Inventors:

- ATLANTA GA, US
Johann C Brandes - Atlanta GA, US

Assignee:

EMORY UNIVERSITY - ATLANTA GA

International Classification:

A61K 31/513
A61K 45/06
A61K 31/337

Abstract:

This disclosure relates to the uses of compounds that target an interaction between CHFR and PARP1. In certain embodiments, the disclosure relate to treating cancer by administering a mitotic inhibitor such as a taxane and a vinca alkaloid in combination with a compound that inhibits CHFR and PARP1 interactions, such as 5-((1-benzyl-1H-indol-3-yl)methylene)-1-(3,4-dimethylphenyl)pyrimidine-2,4,6(1H,3H,5H)-trione, derivatives or salts thereof, optionally in further combination with a third anti-cancer agent.

US Patent:

20140187537, Jul 3, 2014

Filed:

Jan 2, 2014

Appl. No.:

14/146039

Inventors:

Johann C. Brandes - Atlanta GA, US

Assignee:

EMORY UNIVERSITY - Atlanta GA

International Classification:

C12Q 1/68
A61K 31/337
A61K 31/4184
A61K 31/502
A61K 31/55
A61K 31/496
A61K 31/166

US Classification:

514215, 435 611, 51425408, 4352872, 514449, 514248, 514394

Abstract:

This disclosure relates to diagnostic and therapeutic methods and systems related thereto. In certain embodiments, the disclosure contemplates methods of improving chemotherapy treatments by administering chemotherapy agents, analyzing CHFR gene expression, methylation, or both, and determining an appropriate therapeutic strategy. Analysis of data herein revealed that reduced CHFR expression levels was a predictor of improved overall survival of subject with non-small cell lung cancer.